Replies to post #56202 on Biotech Values

[DewDiligence]

>MNTA, just recovering from insanity.<

That’s probably all it is—an absurdly low valuation can be a strong catalyst in its own right.

>…so much easier trying to buy "busted" biotechs<

Actually, I don’t consider MNTA busted in terms of its fundamentals. I use that characterization for biotechs who had a major clinical/regulatory failure and have little remaining assets of value other than cash on the balance sheet. MNTA is certainly not in that category.